GeneReach Biotechnology (4171) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneReach Biotechnology (4171) has a cash flow conversion efficiency ratio of 0.011x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$6.28 Million ≈ $197.92K USD) by net assets (NT$581.48 Million ≈ $18.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4171 company net worth for the company's overall valuation and market capitalisation.
GeneReach Biotechnology - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how GeneReach Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GeneReach Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneReach Biotechnology ranked by their cash flow conversion efficiency. Explore earnings quality score of GeneReach Biotechnology to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Abko Co. Ltd
KQ:129890
|
-0.134x |
|
Horizon Space Acquisition I Corp. Ordinary Shares
NASDAQ:HSPO
|
0.046x |
|
China Crystal New Material
KQ:900250
|
-0.016x |
|
Hub Cyber Security Ltd. Ordinary Shares
NASDAQ:HUBC
|
0.055x |
|
Auking Mining Ltd
AU:AKN
|
-0.199x |
|
Skyline Builders Group Holding Limited Class A Ordinary Shares
NASDAQ:SKBL
|
-0.285x |
|
DK&D Co.Ltd
KQ:263020
|
0.078x |
|
Quickstep Holdings Ltd
AU:QHL
|
2.197x |
Annual Cash Flow Conversion Efficiency for GeneReach Biotechnology (2017–2025)
The table below shows the annual cash flow conversion efficiency of GeneReach Biotechnology from 2017 to 2025. View 4171 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$596.72 Million ≈ $18.80 Million |
NT$-13.52 Million ≈ $-425.80K |
-0.023x | +29.25% |
| 2024-12-31 | NT$725.49 Million ≈ $22.86 Million |
NT$-23.22 Million ≈ $-731.68K |
-0.032x | +28.61% |
| 2023-12-31 | NT$862.44 Million ≈ $27.17 Million |
NT$-38.67 Million ≈ $-1.22 Million |
-0.045x | -113.83% |
| 2022-12-31 | NT$1.10 Billion ≈ $34.74 Million |
NT$357.63 Million ≈ $11.27 Million |
0.324x | +1.12% |
| 2021-12-31 | NT$1.09 Billion ≈ $34.28 Million |
NT$348.99 Million ≈ $11.00 Million |
0.321x | +62.01% |
| 2020-12-31 | NT$857.76 Million ≈ $27.02 Million |
NT$169.82 Million ≈ $5.35 Million |
0.198x | +1148.98% |
| 2019-12-31 | NT$593.05 Million ≈ $18.68 Million |
NT$-11.19 Million ≈ $-352.64K |
-0.019x | -202.24% |
| 2018-12-31 | NT$311.15 Million ≈ $9.80 Million |
NT$5.74 Million ≈ $180.97K |
0.018x | +167.78% |
| 2017-12-31 | NT$250.63 Million ≈ $7.90 Million |
NT$-6.83 Million ≈ $-215.06K |
-0.027x | -- |
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more